RVTY · 8-K · 20260804PR000022

Acquisition / Partnership / Divestiture

REVVITY, INC. · 2026-08-04 · Importance 65 · Surprise 60 · Contradicted

Revvity entered into a definitive agreement to divest its China Immunodiagnostics business, referred to as China IDX. China IDX represented approximately 6% of Revvity’s total fiscal 2025 revenue, implying a business scale of roughly $174 million based on 2025 revenue of $2.9 billion. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. The company’s pro forma 2026 results and guidance exclude China IDX, including its $711 million second-quarter pro forma revenue base and full-year revenue outlook.

Key facts

• Company entered into a definitive agreement to divest its Immunodiagnostics business in China (China IDX). source
• The China IDX divestiture transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. source
• China IDX represented approximately 6% of the Company’s total revenue in fiscal year 2025. source

Impact estimates